Satellos Announces Completed Enrollment of Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
Satellos Bioscience, a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it...
Sarcomatrix to Present its Latest Advancements in the Development of its Lead Drug Candidate, S-969
Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO & Investor...
Upcoming Exon 44 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
Exon 44 skipping therapies represent a promising area in the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness...
Russian Biotech Company Generium has Begun Clinical Trials of a Gene Therapy for Duchenne Muscular Dystrophy
Clinical studies for a therapy for Duchenne muscular dystrophy have begun at Sirius University and the Russian biotech business Generium. At a gathering at...
Cumberland Pharmaceuticals Announces Fantastic Results from Phase 2 FIGHT Duchenne Trial in DMD Heart Disease
Cumberland Pharmaceuticals, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase...